GlassScriptPhysician profile
Sally B Frankl
NPI 1710076054
$12,505.53
in general payments reported to CMS, 2019-2025
39 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,500 · 2020: $808 · 2021: $1,701 · 2022: $2,009 · 2023: $2,575 · 2024: $1,566 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,951.00 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,387.35 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,236.91 | 2019-2025 | Farxiga, Wainua, Breztri |
| E.R. Squibb & Sons, L.L.C. | $989.29 | 2019-2025 | Camzyos |
| Abbvie INC. | $685.56 | 2021-2025 | |
| Abbott Laboratories | $644.70 | 2019-2023 | Proclaim, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $602.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $477.34 | 2022-2025 | |
| Lilly USA, LLC | $373.39 | 2019-2024 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $368.23 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $352.11 | 2023-2025 | Amvuttra, Onpattro |
| Akcea Therapeutics, INC. | $345.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.07 | 2022-2024 | |
| Glaxosmithkline, LLC. | $280.95 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $279.56 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Frankl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.